Experimental and clinical studies on the antituberculous activity of rifampicin alone or combined with other drugs.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000818:Animals; D003470:Culture Media; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009161:Mycobacterium / Q000187:drug effects*; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D009929:Organ Size; D012293:Rifampin / Q000494:pharmacology* / Q000627:therapeutic use; D013154:Spleen / Q000187:drug effects; D013307:Streptomycin / Q000627:therapeutic use; D013997:Time Factors; D014376:Tuberculosis / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000382:microbiology
D000636:Aminosalicylic Acids; D003470:Culture Media; D004338:Drug Combinations; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin